A Phase I/II, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Tor Kinase Inhibitor (AZD8055) in Asian Patients With Advanced Stage Hepatocellular Carcinoma (HCC) and With Mild or Moderate Hepatic Impairment.
Phase of Trial: Phase I/II
Latest Information Update: 09 Jul 2012
At a glance
- Drugs AZD 8055 (Primary)
- Indications Liver cancer
- Focus Adverse reactions; Biomarker; Pharmacokinetics
- 30 Jan 2012 Actual patient number is 26 according to ClinicalTrials.gov.
- 30 Jan 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 30 Jan 2012 Planned end date changed from 1 Feb 2012 to 1 Dec 2011 as reported by ClinicalTrials.gov.